{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["EVOLVE104"]],"indication":"advanced urothelial and squamous cell carcinomas","name":"EIU-104101","nct_id":"NCT07217171","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=eiu-104101-nct07217171. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Active Study Drug","label":"Phase 1a Cohort 1; dose level 1","type":"EXPERIMENTAL"},{"description":"Active Study Drug","label":"Phase 1a Cohort 2; dose level 2","type":"EXPERIMENTAL"},{"description":"Active Study Drug","label":"Phase 1a Cohort 3; dose level 3","type":"EXPERIMENTAL"},{"description":"Active Study Drug","label":"Phase 1a Cohort 4; dose level 4","type":"EXPERIMENTAL"},{"description":"Active Study Drug","label":"Phase 1a Cohort 5; dose level 5","type":"EXPERIMENTAL"},{"description":"Active Study Drug","label":"Phase 1a Cohort 6; dose level 6","type":"EXPERIMENTAL"},{"description":"Active Study Drug","label":"Phase 1a Cohort 7; dose level 7","type":"EXPERIMENTAL"},{"description":"Active Study Drug","label":"Phase 1a Cohort 8; dose level 8","type":"EXPERIMENTAL"},{"description":"Active Study Drug","label":"Phase 1a Cohort 9; dose level 9","type":"EXPERIMENTAL"},{"description":"Active Study Drug","label":"Phase 1a Cohort 10; dose level 10","type":"EXPERIMENTAL"},{"description":"Active study drug","label":"Phase 1b Cohort 1; dose level TBD","type":"EXPERIMENTAL"},{"description":"Active study drug","label":"Phase 1b Cohort 2; dose level TBD","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2031-01-29","type":"ESTIMATED"},"conditions":["Bladder Cancer","Squamous Cell Carcinoma of the Lung","Esophageal Squamous Cell Carcinoma","Tongue Squamous Cell Carcinoma","Cutaneous Squamous Cell Cancer","Penile Squamous Cell Carcinoma","Anal Squamous Cell Carcinoma","Vulvar Squamous Cell Carcinoma","Cervical Squamous Cell Carcinoma","Vaginal Squamous Cell Carcinoma","Urethral Squamous Cell Carcinoma"],"enrollment":{"count":160,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"EVOLVE104","otherNames":[],"type":"DRUG"},{"name":"EVOLVE104","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-15","lead_sponsor":"EvolveImmune United, Inc","official_title":"A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2029-01-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Baseline, through study completion, an average of 10 months."},{"measure":"Number of patients with Dose Limiting Toxicities (DLTs)","timeFrame":"Baseline, through study completion, an average of 10 months."},{"measure":"To determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) for EVOLVE104","timeFrame":"Baseline, through study completion, an average of 10 months."},{"measure":"To determine the recommended phase 2 dose (RP2D) of EVOLVE104","timeFrame":"Safety evaluations will be done as described above. PK and PD to be done each cycle (28 days) at pre-dose and post dose starting Day 1 at various time points, dependent upon treatment regimen assigned, through study completion, an average of 10 months."}],"references":[],"start_date":{"date":"2025-11-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas","url":"https://clinicaltrials.gov/study/NCT07217171"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/eiu-104101-nct07217171"}